<DOC>
	<DOCNO>NCT02383550</DOCNO>
	<brief_summary>This study design demonstrate Tysabri effective maintain cognition MS patient 5 year continuous treatment . During second period 36 month , extension study assess evolution cognitive function Tysabri treat MS patient use Symbol Digit Modalities Test ( SDMT ) CogState battery test .</brief_summary>
	<brief_title>Cognitive Evolution Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension</brief_title>
	<detailed_description>Tysabri reduce relapse frequency , slow progression preserve cognitive function compare placebo per AFFIRM trial . The benefit relapse rate progression appear sustain longer-term study STRATA . In clinical practice however despite stable EDSS patient often complain cognitive deterioration . The investigator ' preliminary result first pilot study show cognition Tysabri treat MS patient two year , measure SDMT Cogstate battery maintain , include ability learn . The investigator ' final data present American Academy Neurology ( AAN ) 2015 . The Symbol Digit Modalities Test ( SDMT ) sensitive validate test cognition MS. CogState offer standardized battery cognitive test frequently use clinical research field dementia Parkinson 's disease . The CogState battery test consist Detection test ( process speed ) , Identification test ( attention ) , One Back test ( work memory ) , International Shopping List test ( verbal learning ) Groton Maze Learning test ( reason problem solve ) confirm validate result SDMT MS patient well examine cognitive domain . The Beck Depression Inventory-II [ Beck 1996 ] validate well recognize clinical research tool depression field multiple sclerosis . Together test do prospectively assess evolution cognitive function Tysabri treat MS patient long term .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Patients complete original study willing continue extension . Patients cognitive decline cause MS ( i.e. , PML , stroke , sleep apnea , neurodegenerative disorder , brain tumor ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognition</keyword>
</DOC>